End Brain Cancer Initiative teams with Nuvation Bio on glioma study education

The End Brain Cancer Initiative has partnered with Nuvation Bio to educate patients and caregivers about the SIGMA Phase 3 study for Grade 2 or 3 glioma. The collaboration aims to help people with IDH1-mutant brain cancer understand trial options as two parts of the study continue enrolling.

Why it matters: - Grade 2 and Grade 3 gliomas are aggressive brain cancers where access to clinical trials can shape treatment options and outcomes. - Patient-facing education can help patients, caregivers and clinicians better understand whether a study is relevant before appointments and treatment decisions. - The partnership centers on SIGMA, a Phase 3 trial of investigational safusidenib in IDH1-mutant glioma.

What happened: - The End Brain Cancer Initiative partnered with Nuvation Bio to provide disease education about the SIGMA trial. - The education effort is aimed at brain cancer patients with Grade 2 or Grade 3 glioma. - More information is available through the SIGMA patient information page.

The details: - SIGMA is evaluating safusidenib in IDH1-mutant glioma. - Part 1 studied efficacy, safety and pharmacokinetics in participants with recurrent or progressive IDH1-mutant World Health Organization Grade 2 or Grade 3 glioma. - Part 1 is no longer enrolling. - Part 2 is evaluating maintenance safusidenib versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma after standard-of-care radiation or chemoradiation and adjuvant temozolomide. - Part 2 is randomized, double-blind and placebo-controlled. - Part 2 is now enrolling. - Part 3 is evaluating safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who received surgery as their only treatment. - Part 3 is an open-label, single-arm cohort. - Part 3 is now enrolling. - Nuvation Bio is a global oncology company with a pipeline that includes taletrectinib, safusidenib and a drug-drug conjugate program. - Nuvation Bio was founded in 2018 by David Hung, M.D., who previously founded Medivation. - Nuvation Bio has offices in New York, San Francisco, Boston and Shanghai. - The End Brain Cancer Initiative is a 501(c)(3) nonprofit patient advocacy organization focused on disease education, awareness, outreach, patient access and improving standard of care. - The organization says it works to ensure patients with brain cancer, brain tumors or metastatic disease to the brain have access to advanced diagnostics, treatments, specialists and clinical trial participation.

Between the lines: - The partnership is less about launching a new study than about improving awareness of an already active trial program. - By focusing on education, the groups are trying to lower the barrier for patients who may qualify for SIGMA but do not yet know the trial exists. - The split across multiple trial parts suggests Nuvation Bio is studying safusidenib in different glioma subgroups and treatment settings.

What's next: - Patients, caregivers and healthcare providers can learn more at the SIGMA patient information page. - Part 2 and Part 3 of SIGMA are currently enrolling. - Nuvation Bio says safusidenib remains part of its broader oncology pipeline.